Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith E Epstein

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Vaccine|June 5, 2012
A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccinesMatthew B Laurens, Christopher J Duncan, Judith E Epstein, et al.
Plos One|August 20, 2021
IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOSMartha Sedegah, Michael R Hollingdale, Harini Ganeshan, et al.
Plos One|February 13, 2025
Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopesHarini Ganeshan, Jun Huang, Maria Belmonte, et al.
Nature Communications|June 13, 2022
Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in AfricaJoana C Silva, Ankit Dwivedi, Kara A Moser, et al.
Plos One|September 12, 2014
Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesMartha Sedegah, Michael R Hollingdale, Fouzia Farooq, et al.
Vaccine|October 16, 2015
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccinesThomas L Richie, Peter F Billingsley, B Kim Lee Sim, et al.
Human Gene Therapy|September 14, 2002
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routesJudith E Epstein, Edward J Gorak, Yupin Charoenvit, et al.
Human Vaccines|December 1, 2009
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malariaStephen L Hoffman, Peter F Billingsley, Eric James, et al.
Vaccine|April 8, 2004
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02AJudith E Epstein, Yupin Charoenvit, Kent E Kester, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2020
Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria InfectionKirsten E Lyke, Alexandra Singer, Andrea A Berry, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Vaccine|June 5, 2012
A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccinesMatthew B Laurens, Christopher J Duncan, Judith E Epstein, et al.
Plos One|August 20, 2021
IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOSMartha Sedegah, Michael R Hollingdale, Harini Ganeshan, et al.
Plos One|February 13, 2025
Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopesHarini Ganeshan, Jun Huang, Maria Belmonte, et al.
Nature Communications|June 13, 2022
Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in AfricaJoana C Silva, Ankit Dwivedi, Kara A Moser, et al.
Plos One|September 12, 2014
Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesMartha Sedegah, Michael R Hollingdale, Fouzia Farooq, et al.
Vaccine|October 16, 2015
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccinesThomas L Richie, Peter F Billingsley, B Kim Lee Sim, et al.
Human Gene Therapy|September 14, 2002
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routesJudith E Epstein, Edward J Gorak, Yupin Charoenvit, et al.
Human Vaccines|December 1, 2009
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malariaStephen L Hoffman, Peter F Billingsley, Eric James, et al.
Vaccine|April 8, 2004
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02AJudith E Epstein, Yupin Charoenvit, Kent E Kester, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2020
Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria InfectionKirsten E Lyke, Alexandra Singer, Andrea A Berry, et al.
Pageof 5